The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
01-May-13
$NA
Target:
Jeminex’s Industrial & Safety division
Acquiror:
Bunzl plc
Advised AMP Capital on the sale of Jeminex’s Industrial & Safety division, Australia’s second largest industrial and safety business with branches across Australia, to Bunzl plc
20-Dec-12
$NA
Target:
Germanischer Lloyd
Acquiror:
Det Norske Veritas
Advised Det Norske Veritas on its merger with Germanischer Lloyd to create the third largest player in the Testing, Inspection and Certification industry, focused on ship classification, oil & gas and energy
12-Nov-12
~$100 million
Target:
Aurelian Oil & Gas PLC
Acquiror:
San Leon Energy PLC
Advised Aurelian Oil & Gas, an AIM-listed E&P company primarily focused on natural gas exploration in Central Europe, on its recommended merger with AIM-listed peer San Leon Energy PLC
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
23-Apr-12
$2.0 billion
Target:
Moorebank Intermodal Terminal
Acted as independent advisor to the Australian Government in a peer review of the proposed intermodal terminal linking Sydney’s major port with Australia’s road and rail system
15-Mar-12
$650 million
Target:
Viridian Group
Advised the Board of Viridian, the leading energy utility company in the all-Ireland market, on its refinancing comprising the issue of €313 million and $250 million notes due April 2017
01-Mar-12
$NA
Target:
Minority stake in Stadler Rail
Acquiror:
Peter Spuhler
Advised Capvis, one of the leading buyout firms in Switzerland and one of the main mid-market private equity firms in German-speaking Europe, on the staged exit from of its 20% minority stake in Stadler Rail, by selling to Peter Spuhler, CEO and majority shareholder in Stadler Rail
20-Jan-12
$NA
Target:
Solar PV power plant in Italy
Acquiror:
Antin Infrastructure Partners
Advised Antin Infrastructure Partners on the acquisition of a c.20MW solar PV power plant in Italy
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
08-Jun-11
$1.7 billion
Target:
Citigroup (selected private equity assets)
Acquiror:
AXA Private Equity
Advised AXA Private Equity, a leading European diversified private equity firm, on its acquisition of a $1.7 billion portfolio of limited partnership interests in private equity buyout funds and a portfolio of direct stakes in companies from Citigroup
18-May-11
$146 million
Target:
Portfolio of solar PV power plants from Kinexia SpA
Acquiror:
Antin Infrastructure Partners
Advised Antin Infrastructure Partners on the acquisition of a portfolio of solar PV power plants in Italy
13-May-11
$NA
Target:
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
02-Mar-11
$NA
Target:
TSmarine
Acquiror:
Fugro N.V.
Advised CHAMP Ventures on the sale of its portfolio company TSmarine, a provider of subsea services to the offshore oil and gas industry, to Fugro, among the world's leading service providers for the collection and interpretation of data relating to the earth's surface and sub-surface and for associated services
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
13-Dec-10
$256 million
Target:
Maxinutrition Group Holdings Limited
Acquiror:
GlaxoSmithKline Plc
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
07-Jul-10
$1.8 billion
Target:
Viridian
Acquiror:
ESB
Advised Viridian, one of the leading electricity companies in the all Ireland market, on the sale of NIE, its regulated electricity transmission and distribution businesses in Northern Ireland, to ESB, the state owned vertically integrated utility in Republic of Ireland
06-Apr-10
$153 million
Target:
Virgin Money Holdings (UK) Limited
Acquiror:
W.L. Ross & Co. LLC
Advised Virgin Money Holdings (UK) Limited, Virgin Group’s financial services arm, on the structuring of an investment of £100m from WL Ross & Co.
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
18-Sep-09
$81 million
Target:
UKAEA Limited
Acquiror:
Babcock International Group plc
Advised United Kingdom Atomic Energy Authority Non Departmental Public Body, arm of the UK Government, on the sale of UKAEA Limited, its commercial nuclear decommissioning services business, to Babcock International Group plc
21-May-09
$111 million
Target:
Shanks Group plc
Acted as Financial Adviser and Sponsor to Shanks Group plc, a leading European waste management group, on its rights issue
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company